Meeting
2013 ASCO Annual Meeting
Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
Authors
Rosario García Campelo
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Rosario García Campelo , Enriqueta Felip , Bartomeu Massuti , Margarita Majem , Enric Carcereny , Felipe Cardenal , Miguel Angel Molina-Vila , Alex Martinez Marti , Juan Luis Marti-Ciriquian , Guillermo Alonso-Jaudenes Curbera , Cinta Pallares , Ramon Palmero , Maria Carmen Gonzalez-Arenas , Clara Mayo-de las Casas , Maria Sanchez-Ronco , Rafael Rosell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
DNA Repair and Apoptosis
Clinical Trial Registration Number
NCT0151317
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2581)
DOI
10.1200/jco.2013.31.15_suppl.2581
Abstract #
2581
Poster Bd #
7A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
First Author: Rosario Garcia Campelo
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang
Poster
2015 ASCO Annual Meeting
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
First Author: Daniel Shao-Weng Tan
Poster
2018 ASCO Annual Meeting
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).
First Author: Rosario Garcia Campelo